Bluejay Diagnostics, Inc. - Form 8-K Filing

Bluejay Diagnostics, Inc. has issued a Form 8-K detailing the progress of its SYMON-II clinical trial. The company announced the successful enrollment of 624 patients, nearing the trial's target of 750. The SYMON-II trial evaluates the Symphony™ platform for interleukin-6 (IL-6) testing in critical care settings for sepsis triage and monitoring. The company expects to complete enrollment within the next 2-3 months. This milestone is crucial for the clinical validation of the Symphony™ IL-6 test, which aims to provide rapid, near-patient results to aid clinicians in acute care environments. Bluejay plans to use the trial data to support a 510(k) application to the FDA. The press release also includes information about the Symphony IL-6 Test, the SYMON Clinical Study Program, and forward-looking statements regarding the company's development and regulatory path.